vutiglabridin (HSG4112) / Glaceum 
Welcome,         Profile    Billing    Logout  

3 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
vutiglabridin (HSG4112) / Glaceum
NCT05197556: A Study to Evaluate the Safety and Efficacy of HSG4112 in Overweight and Obese Patients

Completed
2
81
RoW
HSG4112, 2-(8,8 dimethyl 2,3,4,8,9,10 hexahydropyrano[2,3 f]chromen 3 yl) 5 ethoxyphenol, Placebo
Glaceum, Gangnam Severance Hospital, Seoul National University Bundang Hospital, Korea University Anam Hospital, Seoul National University Hospital, SMG-SNU Boramae Medical Center
Obesity
12/22
04/23
NCT06329141: A Study to Assess the Efficacy and Safety of Vutiglabridin in Early Parkinson's Disease Patients

Not yet recruiting
2
90
NA
Vutiglabridin, HSG4112, 2-(8,8 dimethyl 2,3,4,8,9,10 hexahydropyrano[2,3 f]chromen 3 yl) 5 ethoxyphenol, Placebo
Glaceum, The Catholic University of Korea, Kyunghee University Medical Center, Korea University Guro Hospital, Samsung Medical Center, Severance Hospital, Inje University
Parkinson Disease
12/25
06/26
NCT05310032: A Study to Investigate the Safety, Tolerability, Pharmacokinetic/Pharmacodynamic Characteristics and Food Effect of HSG4112 in High Doses

Completed
1
36
RoW
HSG4112, 2-(8,8 dimethyl 2,3,4,8,9,10 hexahydropyrano[2,3 f]chromen 3 yl) 5 ethoxyphenol, Placebo
Glaceum, Seoul National University Hospital
Obesity
12/22
03/23

Download Options